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Abstract
Gold and copper nanoparticles have been widely investigated for photothermal therapy of cancer.
However, degradability and toxicity of these nanoparticles remain concerns. Here, we compare
hollow CuS nanoparticles (HCuSNPs) with hollow gold nanospheres (HAuNS) in similar particle
sizes and morphology following intravenous administration to mice. The injected pegylated
HCuSNPs (PEG-HCuSNPs) are eliminated through both hepatobiliary (67 percentage of injected
dose, %ID) and renal (23 %ID) excretion within one month post injection. By contrast, 3.98 %ID
of Au is excreted from liver and kidney within one month after i.v. injection of pegylated HAuNS
(PEG-HAuNS). Comparatively, PEG-HAuNS are almost non-metabolizable, while PEG-
HCuSNPs are considered biodegradable nanoparticles. PEG-HCuSNPs do not show significant
toxicity by histological or blood chemistry analysis. Principal component analysis and 2-D peak
distribution plots of data from matrix-assisted laser desorption ionization-time of flight imaging
mass spectrometry (MALDI-TOF IMS) of liver tissues demonstrated a reversible change in the
proteomic profile in mice receiving PEG-HCuSNPs. This is attributed to slow dissociation of Cu
ion from CuS nanoparticles along with effective Cu elimination for maintaining homeostasis.
Nonetheless, an irreversible change in the proteomic profile is observed in the liver from mice
receiving PEG-HAuNS by analysis of MALDI-TOF IMS data, probably due to the non-
metabolizability of Au. This finding correlates with the elevated serum lactate dehydrogenase at 3
months after PEG-HAuNS injection, indicating potential long-term toxicity. The comparative
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results between the two types of nanoparticles will advance the development of HCuSNPs as a
new class of biodegradable inorganic nanomaterials for photothermal therapy.
Keywords
hollow CuS nanoparticles (HCuSNPs); hollow gold nanospheres (HAuNS); degradability;
toxicity; matrix-assisted laser desorption ionization-time of flight imaging mass spectrometry
(MALDI-TOF IMS)
The design and synthesis of multi-functional nanomaterials have provided potential
applications in biomedical fields such as molecular imaging and drug delivery. Interest in
using inorganic nanostructures such as gold and CuS nanoparticles has surged in the last
decades as these particles exhibit strong optical absorption at near-infrared (NIR)
wavelengths (650–900 nm). They convert optical energy into thermal energy, and deposit
benign NIR optical energy into tumors for thermal ablation of tumor cells.1–8 Gold
nanostructures (nanoshells,1 nanorods,2 nanocages,3 and hollow nanospheres4) are widely
reported as photothermal coupling agents to enhance the efficacy of photothermal therapy.
Although the metallic gold nanoparticles with bioinert properties show great promise for
clinical applications,9, 10 they are non-biodegradable, raising concerns regarding their long-
term metabolism.11–13
Semiconductor CuS nanoparticles (CuSNPs) are a class of inorganic photo-absorbers that
provide an alternative to gold analogs. CuSNPs with particle sizes 3 nm5 and 11 nm,6, 14
flower-like CuS superstructures (~1 μm in diameter),7 and Cu9S5 plate-like nanocrystals
(~70 nm × 13 nm)8 have intense optical absorption at NIR region. In contrast to exogenous
gold, copper is essential for human health.15 In adults, the highest safe intake level of Cu is
10 mg daily,16 indicating that CuS nanoparticles may be metabolized by humans. However,
critical pharmacological parameters such as body disposition and long-term metabolism of
these CuSNPs remain unknown. Moreover, there is a paucity of data regarding the
cytotoxicity profile of the CuSNPs.5, 8 This knowledge is essential for clinical applications
of CuS nanomaterials.
In this study, we compared degradability and toxicity between the two types of photothermal
nanoparticles, i.e. hollow gold nanospheres (HAuNS)17 and hollow CuS nanoparticles
(HCuSNPs),18 in mice following systemic administration. The two nanoparticles were
formulated with similar particle size and morphology. They were both surface-modified
with polyethylene glycol (PEG) in order to evade uptake by monophagocytic systems.
Therefore, their pharmacokinetics and disposition were contingent on the intrinsic
characteristics of the nanoparticles such as crystal structures and chemical composition. In
addition to routine toxicity evaluation, matrix-assisted laser desorption ionization (MALDI)-
time of flight (TOF) imaging mass spectrometry (IMS) was employed to analyze changes in
the molecular profile of liver in mice before and after the injection. Understanding the fate
and toxicity profile of these two nanoparticles in vivo will provide valuable information
designing biodegradable and safe inorganic nanomaterials for photothermal therapy.
RESULTS AND DISCUSSION
Transmission electron microscopy (TEM) illustrated that HCuSNPs (~70 nm) and HAuNS
(~50 nm) were morphologically similar; both were spherical shape and hollow interiors
(Figures 1A and 1B). Their particle size distributions were both in the range of 50 – 100 nm,
consistent with favorable pharmacokinetics and enhanced permeability and retention effect
in tumor following systemic administration.19 Both nanoparticles displayed intense optical
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absorbance in the NIR region (Figure 1C). Following pegylation, at equivalent mass
concentrations (i.e. 27 μg/mL of Cu or Au), PEG-HCuSNPs and PEG-HAuNS had similar
absorption intensities at 900 nm (0.48 v.s. 0.52 A.U.). Because of the similarity of the
particles in morphology and absorption at 900 nm, PEG-HCuSNPs and PEG-HAuNS
exhibited identical photothermal ablation effect on cancer cells upon 900-nm NIR laser
treatment (Figure S1). In nude mice bearing A549 human lung adenocarcinoma xenografts,
real-time infrared thermal imaging illustrates that the temperature of tumor area in mice
pretreated with PEG-HCuSNPs (20 mg/kg of Cu) or PEG-HAuNS (20 mg/kg of Au)
elevates to 53°C at 1 min after the laser irradiation with power intensity of 2.0 W/cm2
(Figure S2). These results suggest that PEG-HCuSNPs and PEG-HAuNS have similar
efficacies of photothermally induced tumor destruction, since elevation of temperature to
51°C for 100 s can cause irreversible thermal damage to cells or tissues.20, 21
To compare their fate in vivo, we first examined the biodistribution of Cu or Au in major
organs after a single i.v. injection of PEG-HCuSNPs or PEG-HAuNS in BALB/c mice. Both
liver and spleen retained larger amounts of Cu or Au than other organs during the entire 3-
month postinjection period (Figure 2A). The accumulation of the two nanoparticles in liver
and spleen at 1 day could be attributed to short term effect of the pegylation.22 PEG
modification of both nanoparticles is likely to take effect during the first few hours after
administration, while the PEG coating may disappear thereafter based on chain length and
charged groups of the PEG molecules.22, 23 Intriguingly, the Cu level in liver decreased
much faster than Au level after 1 day. The Cu level in liver was 1.1 ± 0.1 percentage of
injected dose per gram (%ID/g) at 3 months after injection of PEG-HCuSNPs, which was
only 5% of the amount at 1 day postinjection (Figure 2B). However, the injected PEG-
HAuNS remained 11.4 ± 1.8 %ID/g in liver after 3 month, which was 70% of the amount at
1 day postinjection. Similar accumulation profile was found in the spleen. At 3 months
postinjection, there was 6.9% of Cu remaining in spleen compared to 1-day’s level. In
contrast, 94.6% of the injected PEG-HAuNS remained after 3 months. The Cu levels in
lung, kidney and heart also decreased much faster than the Au levels (Figure 2A). There was
no retention of Cu in all major organs except liver or spleen after 3 months, while a
significant amount of Au in major organs remained. The distribution results demonstrated
that the PEG-HCuSNPs were efficiently eliminated from the body.
To understand how HCuSNPs were cleared from the body, we collected urine up to one
month following i.v. injection. Interestingly, the urine collected following injection of PEG-
HCuSNPs was noticeably greenish (Figure S3, green arrows). Following high speed
centrifugation (15,871 g, 15 min), a dark green pellet was observed, whereas the supernatant
turned yellow (Figure S3, blue arrows). This result prompted us to hypothesize that some
CuSNPs were excreted from the kidney, since CuSNPs appear green in aqueous solution.
However, the original structure of HCuSNPs was not detected under TEM of the urine
sample collected at 24 h following PEG-HCuSNPs injection. Instead, there were a few small
CuS nanoparticles (SCuSNPs) in the urine (Figure 3A, arrows). TEM at higher
magnification revealed particles with crystal lattice structures of 3–5 nm in diameter (Figure
3A, inlets, arrows). HCuSNPs were composed of hexagonal CuS crystals with an average
crystalline size of 12.5 nm, calculated by the Debye-Scherrer formula.24 Our TEM imaging
illustrated that the shell of HCuSNPs was porous and composed of small particles of 11–12
nm in diameter (Figure 3B, arrow). This observation was in line with formation of the
HCuSNPs by the Kirkendall effect.24 The CuSNPs were formed on the outside and inside
surfaces of the CuS shell through sulfidation. The produced CuS shell was a poly-crystalline
structure, and the holes in the shell became a shortcut for mass diffusion and transference.24
We thus presumed that the porous CuS shell structure may facilitate its disintegration in
vivo. Imaging of pellets from plasma collected at 3 h postinjection of PEG-HCuSNPs
indicated that most HCuSNPs were intact (Figure 3C). However, there were a small number
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of SCuSNPs with particle sizes of 4–5 nm visualized in the same pellet (Figures 3D and 3E,
arrows). Energy dispersion spectrum (EDS) analysis confirmed that these small particles
observed in the urine and plasma were CuS crystallites with similar Cu-to-S atomic ratio to
HCuSNPs (Figure S4). Since the effective size cutoff of glomerular filtration was 10 nm for
the rapid renal clearance of small nanoparticles such as gold nanoparticles and quantum
dots,25–27 and since the size and composition of the SCuSNPs disintegrated in the plasma
was in agreement with that observed in the urine (3–5 nm), we concluded that a small
number of PEG-HCuSNPs disintegrated into SCuSNPs in blood, followed by directly renal
excretion.
Quantitative analysis of Cu in urine including supernatant (Cu ions) and pellet (SCuSNPs) in
the 1-month study delineated a continuous renal excretion following i.v. injection of PEG-
HCuSNPs (Figure 4A). The cumulative Cu excreted from the kidney was 22.7 ± 6.6
percentage of injected dose (%ID), of which the amount of Cu in form of SCuSNPs only
accounted for 4.8%. The Cu ion (95.2%) was the dominant form in the urine. This result
supported our TEM observation that only small amounts of SCuSNPs appeared in plasma.
Renal excretion of Cu in both particulate and ionic forms displayed a two-phase elimination
profile (Figure 4A), an initial fast excretion phase (0 – 12 h) followed by secondary slow
excretion phase (12 h – 30 d). Ionic Cu presumably was the product of degradation and/or
biotransformation of HCuSNPs or the protein-bound SCuSNPs. This result correlated with
the fast elimination of Cu in the major organs, evidencing that the HCuSNPs can be
metabolized in the body.
In contrast, analysis of Au in urine following i.v. injection of PEG-HAuNS showed very
little renal excretion of Au (Figure 4B). The cumulative Au excreted from the kidney was
only 0.08 ± 0.02 %ID throughout 1 month postinjection. There was no discernible gold
nanocrystal in urine under TEM imaging (data not shown), although trace amounts of Au
were detected in the urine pellet. The very slow elimination rate of HAuNS indicated that
PEG-HAuNS are almost non-metabolizable.
We looked further into the liver distribution of both PEG-HCuSNPs and PEG-HAuNS, since
liver uptake was the highest among all the investigated organs. Histochemistry with silver
staining was utilized to visualize CuSNPs. The CuSNPs were converted into silver sulfide
particles that exhibited black contrasts under white field light microscopy. As shown in
Figure 5A, there were two forms of CuSNPs present in liver at 1 day postinjection of PEG-
HCuSNPs. The majority were agglomerates or large aggregates of the nanoparticles. The
rest were single or small particle aggregates (Figure 5A, 1 d, upper image). Co-staining with
the macrophage-specific marker, CD68,28 demonstrated that the black agglomerates formed
in liver macrophages (brown staining) – Kupffer cells (Figure 5A, 1 d, lower image). On the
other hand, the small particles were sporadically distributed in either liver interstitium or
hepatocytes. At 1 week postinjection, these small particles almost disappeared without
significant accumulation in hepatocytes (Figure 5A, 1 w, lower image). The number of
nanoparticle-loaded Kupffer cells, as well as the number of agglomerates in each Kupffer
cell, also decreased with time. After 1 month, only a few agglomerates were found in a small
population of Kupffer cells (Figure 5A, 1 m, lower image, arrow). After 3 months, almost no
agglomerates were observed in the liver. This result indicated that the elimination of
CuSNPs in liver may be attributed to Cu metabolism by the hepatocytes through
hepatobiliary excretion.29 Quantitative analysis of Cu in feces proved that 66.9 ± 27.2 %ID
of Cu was excreted through the bile within 1 month post-injection (Figure 6A). Collectively,
the Cu elimination through both renal and hepatobiliary excretion was calculated to be
almost 90 %ID within one month following injection of PEG-HCuSNPs.
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For evaluation of the distribution of HAuNS, we observed the scattering of gold
nanoparticles under dark field light microscopy.30 At 1 day following injection of PEG-
HAuNS, the distribution pattern of gold nanoparticles in liver was found to be similar to that
of the CuSNPs (Figure 5B). However, the elimination of gold in liver was much slower than
that of Cu, as evidenced by significant amounts of gold agglomerates observed in Kupffer
cells after 3 months. The Au excretion from the bile was 3.9 ± 1.8 %ID within 1 month post-
injection (Figure 6B). The total Au elimination from both kidney and liver was only 3.98
%ID within 1 month post-injection.
It was reported that the biodegradable poly(DL-lactide-co-glycolide) (PLGA) microspheres
with 50% and 26% of glycolic acid content injected intramuscularly in rats degraded in vivo
with half-lives of 2 weeks and 12 weeks, respectively.31 In terms of biodegradable
mesoporous silica nanoparticles, half of the nanoparticles were cleared from the body at 4
weeks post i.v. injection.32 Our results demonstrated that about 90% of the PEG-HCuSNPs
were eliminated from mice within one month following i.v. injection. Compared with the
PLGA microspheres and mesoporous silica nanoparticles, the PEG-HCuSNPs were cleared
faster. PEG-HCuSNPs thus can be considered to be biodegradable nanoparticles. In contrast,
the elimination of 40-nm colloidal gold nanoparticles in liver in C57BL mice was reportedly
very slow, with only a 9% fall in the gold content over 6 months following i.v. injection.12
The calculated daily elimination rate was only 0.05%. By extrapolation, a large fraction of
injected gold nanoparticles will remain in the liver even beyond the normal mouse
lifespan.12 In another report, accumulation of 20-nm gold nanoparticles in liver and spleen
in Wistar rats did not decrease after two months.13 Our results here agree with these
observations, indicating gold nanoparticles are almost non-metabolizable or with extremely
long elimination half-lives.
A proposed disposition profile of PEG-HCuSNPs following i.v. injection is shown in
Scheme 1. The major population of blood-circulating PEG-HCuSNPs distributes into tissues
where the HCuSNPs gradually disintegrate into SCuSNPs, further dissociating Cu ions. The
Cu ions are eliminated through both hepatobiliary and renal excretion. Within one month
after administration, about 67% of the injected Cu is eliminated through the bile, and 23%
through the urine. Of the renally excreted Cu, the majority (95.2%) is ionic as a result of
degradation and biotransformation of HCuSNPs or the protein-bound SCuSNPs. The rest
(4.8%) is in SCuSNP form. These SCuSNPs are directly excreted from the kidney during the
initial elimination phase (0–12 h postinjection), and they presumably have specific
zwitterionic coating accessible to urinary excretion rather than forming protein coronas.27
We next examined the cytotoxicity of PEG-HCuSNPs and PEG-HAuNS by a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of mouse macrophage
RAW264.7 cells and primarily cultured mouse hepatocytes.33, 34 We did not observe a
significantly inhibitory effect of PEG-HCuSNPs or PEG-HAuNS on cell proliferation at a
Cu or Au concentration range of 3.2–100 μg/mL (Figure 7A). Since excessive tissue
accumulation of Cu ions is known to cause toxicity, we investigated the cytotoxicity of free
Cu ions. The cell viability was reduced to 35.6% on RAW264.7 cells and 43.3% on mouse
hepatocytes when treated with CuCl2 solution at a Cu concentration of 100 μg/mL,
respectively. Because the solubility product constant Ksp of CuS is 7.9 × 10−37 at 25°C, only
3.2 ± 0.3% of Cu ions were released from the PEG-HCuSNPs in the medium within 24 h
(Figure S5). The low toxicity of PEG-HCuSNPs thus appears to be due to the slow
dissociation rate of Cu ions from CuS. This is supported by the previous report of Cu9S5
nanocrystals displaying a very low cytotoxicity at concentration of 100 ppm on HeLa cells
due to only 3.7 ppm of Cu ions released.8
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Following i.v. injection of a single dose of PEG-HCuSNPs or PEG-HAuNS (20 mg/kg of
Cu or Au per mouse), there were no deaths in any of the experimental groups during the 3-
month period. The mice treated with PEG-HCuSNPs did not show significant increase in
any tested serum biochemical parameters compared to the control mice without any
treatment (Figure 7B). This result indicated that a single dose of PEG-HCuSNPs did not
impair liver or kidney function. Comparatively, there was a noticeable elevation of serum
lactate dehydrogenase (LDH) in mice at 3 months after injection of PEG-HAuNS, although
other biochemical parameters remained normal levels (Figure 7B). This finding implied that
the injection of PEG-HAuNS possibly caused certain long-term toxic effect. Nonetheless,
H&E staining of the liver did not show any apparent change in cellular structures after PEG-
HCuSNPs or PEG-HAuNS injection during the 3-month study (Figure 7C).
In order to understand the effect of these nanoparticles on the body and to determine
whether any resulting changes occurred in the molecular content in tissues, we employed
MALDI-TOF IMS to characterize the differences in the molecular profile of frozen liver
tissue sections from BALB/c mice treated with a single i.v. injection of PEG-HCuSNPs or
PEG-HAuNS. In MALDI-TOF IMS analysis, a laser ablated a 20–80 μm spot radius of
tissue upon which the desorbed ionized proteins were detected using TOF mass
spectrometry and were represented as individual mass peaks in the acquired spectrum (see
Figure S6 workflow). Each mass spectrum contained information of the molecular
composition of one spot. The mass spectra generated at each x, y coordinate were exported
using FlexImaging software for profile analysis, which identified unique differences in
tissue heterogeneity at a spectral (Figure S7) and spatial level (imaging of mass peaks),
respectively. The spectral and spatial differences indicated presence or absence, co-
localization or de-localization of specific proteins. As shown in Figure S7, the average
spectra from the samples after the i.v. administration of PEG-HCuSNPs or PEG-HAuNS
exhibited variations of peak distribution and intensity as compared to samples without
treatment (Control) over time. More importantly, the spectral profiles between the CuS and
Au nanoparticles in the tissue were significantly different indicating remarkable distinction
in the molecular composition within the cells.
To further evaluate this spectral difference, we imported the spectra of each tissue sample
(group) into ClinProtTools software for statistical analysis.35 Using ClinProtTools, p value
of t-test analysis of variance (ANOVA) and difference average analysis were performed to
analyze the peak intensity difference in order to rank a series of differentiated peaks between
the nanoparticle-treated samples and the control. The 2-D peak distribution views were used
to display the distribution of the two most significant peaks among the ranking lists (See
Supporting Information for 2-D Peak Distribution approach). In PEG-HCuSNPs-treated
samples, peaks at 8566 Da and at 4964 Da were identified as the two most statistically
significant peaks according to a p-value t-test ANOVA list (Figure 8A). Peaks at 4964 Da
and at 3458 Da were identified as the two most statistically significant peaks based on a
difference average test (Figure 8B). The 2-D peak distribution plots of these two-peak sets
both demonstrated that the distribution of the liver samples at 1 day (pink ellipse) after
injection of PEG-HCuSNPs departed from that of blank control (blue ellipse). The
maximum variations were observed at 7 days (red ellipse) after the administration that did
not overlap with other samples. Nonetheless, after 3 months the distribution tended to return
to normal levels with some overlap between green and blue ellipses.
As MALDI-TOF IMS collects sequential spectra from spots over the entire tissue section,
information on spatial distribution of all the biomolecules can be obtained. To identify such
change at a spatial level, the above mass peaks (3458 Da, 4964 Da and 8566 Da) were
mapped on the tissue to visualize their distribution and relative abundance (Figure 8C). The
spatial distribution of each of these peaks illustrated significant decreases in intensity and
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varying distribution patterns 1 day after the injection of PEG-HCuSNPs compared with that
of control. The intensity was further diminished after 7 days. However, the expression of
these molecules returned close to normal levels after 3 months. The results from 2-D peak
distribution plots and mass peak imaging clearly demonstrated a reversible difference in
these statistically significant peaks that differentiated between the PEG-HCuSNPs-injected
and control samples. This trend can be representative of the spectral profile of the
nanoparticle-treated samples.
To confirm this trend, we used another statistical method, principle component analysis
(PCA), for identifying the significantly differential peaks in the spectral data (See
Supporting Information for PCA approach). This approach has been outlined for the analysis
of proteomic profiles of cancer patients and biomarker identification.35, 36 The score output
(Figure 8D, top row) demonstrated distinction between the PEG-HCuSNPs-injected and
control samples in the three principal component (PC) coordinates. From plots of PC1 v.s.
PC2, and PC2 v.s. PC3, it was apparent that PC2 accounted for the trend in the distribution
of variation of the peaks. After the injection of PEG-HCuSNPs the distribution of the PC
scores at 1 day (pink dots) or 7 days (red dots) displayed significant deviation from that of
the control (blue dots) along PC2 axis. Nonetheless, after 3 months the distribution along
PC2 axis returned to near normal (green dots v.s. blue dots). The PCA result further
substantiated a reversible variance in the proteomic profile of liver following i.v. injection of
PEG-HCuSNPs.
In PEG-HAuNS-treated samples, the 2-D peak distribution plots of peaks (4737 Da, 4964
Da) and peaks (4964 Da, 14970 Da) identified using the t-test ANOVA list (Figure 9A) and
difference average list (Figure 9B), respectively, depicted departure of peak distributions of
the sample at 1 day after the injection from that of the control. The variations at 7 days after
the injection reached a maximum. There was no distribution (ellipse) overlap between the
samples at 3 months after the injection and the control, although the difference slightly
reduced between them as shown in Figure 9B. Mass peak imaging also showed the
variations in expression of these identified differential peaks (4737 Da, 4964 Da and 14970
Da) at 1 day, 7 days, or 3 months after the injection (Figure 9C). However, the signals of
peaks at 4737 Da and at 14970 Da did not tend to be restored to normal levels after 3
months. The spatial distribution of peak at 4964 remained heterogeneity after 3 months
compared with that of control. In addition, as shown in PCA score output (Figure 9D, top
row), the distribution patterns of PC1, PC2 or PC3 at 1 day (pink dots), 7 days (red dots), or
3 months (green dots) after PEG-HAuNS injection were significantly different from those of
the control (blue dots). These data delineated an irreversible change in the proteomic profile
of the liver following i.v. injection of PEG-HAuNS.
MALDI-TOF IMS is a molecular imaging technology that adds a dimension to classical
proteomics analysis by providing information on the spatial distribution of biomolecules
(e.g. proteins, peptides, lipids, metabolites) in a tissue section.37–40 MALDI-TOF IMS offers
several key advantages including extreme sensitivity, capture of all biomolecular content in
a single spectrum, and production of as many ion maps as the number of detected peaks in
the mass spectrum for one acquisition step. Most importantly, there is no need for
prerequisite knowledge on the molecules to be analyzed by MALDI-TOF IMS.39, 41
Because of these advantages, applications of MALDI-TOF IMS have rapidly grown in the
biomedical research field such as diagnosis and prognosis through analysis and classification
of tissue samples by their proteomic profile.39, 42–44 We, here, applied the MALDI-TOF
IMS to nanotoxicity evaluation through analyzing difference between normal and
nanoparticle-treated liver tissues at a molecular level. Our measurements generated
important information that was complementary to traditional methods of histopathologic and
blood chemistry analysis. First, MALDI-TOF IMS were able to detect subtle changes of
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biomolecules in liver tissue. In both PEG-HCuSNPs and PEG-HAuNS treated liver samples,
variations of proteomic profile by 2-D peak distribution plot, mass peak imaging or PCA
plot were clearly detected, while no significantly histological changes were observed by the
H&E staining analysis. Second, results from MALDI-TOF IMS analysis correlated with the
nanoparticle distribution in liver over time. The variations shown in both mass peak imaging
and plots of statistical analysis at 1 day after injection of the nanoparticles were a result of
singnificant accumulation of the nanoparticles in liver. After 7 days, large amounts of the
remaining nanoparticles in liver produced a cumulative effect on the proteomic profile,
reaching a maximium variation compared to the normal control. Since 95% of the liver-
distributed Cu was eliminated at 3 months after injection of PEG-HCuSNPs, the proteomic
profile tended to return to normal levels. In contrast, because 70% of PEG-HAuNS remained
in the liver at 3 months after injection, the molecular profile was not likely to be restored to
normal. Third, changes of biomolecules in liver detected by MALDI-TOF IMS mirrored the
pharmacologic and toxicity effect of the nanoparticles. The reversible variations of the liver
proteomic profile following injection of PEG-HCuSNPs were in line with the data of the
blood chemistry analysis, substantiating biodegradability as well as little or no toxicity of
the particles. Nonetheless, an irreversible change in the liver proteomic profile at 3 months
after injection of PEG-HAuNS correlated with the elevated serum LDH level, indicating
non-metabolizability and potential long-term toxicity of PEG-HAuNS. Accordingly, the
MALDI-TOF IMS of liver tissues is an accurate and sensitive tool for the evaluation of
nanotoxicity in vivo. This method can be applied to evaluating the toxicity of any other
nanoparticles. Future experiments will be performed to identify those altered biomolecules.
Although Cu is an essential trace element in the body, free Cu ions in excess are toxic. We
have demonstrated little or no toxicity of PEG-HCuSNPs at a single dose of 20 mg/kg Cu.
This is because CuS has very small solubility product constant (7.9 × 10−37). The slow
dissociation of Cu ions, along with effective elimination of Cu ions,45 are believed to
maintain homeostasis without drastically increased toxicity. The level of Cu ions is tightly
regulated by several transporters and chaperones.46 These proteins also prevent cellular
damage from an excess accumulation of Cu by mediating the efflux of Cu from the cell.
Intracellularly, several proteins such as copper-transporting ATPases, as well as
metallothionein (MT)47–49 and glutathione (GSH)50 are complexed with Cu, representing
intracellular transport, storage or detoxication of these ions. Further investigation will focus
on the expression levels of these proteins as well as the Cu excretion mechanisms.
Gold nanoparticles generally show little or no acute toxicity because the bulk material is
bioinert. The HAuNS in this study was synthesized under citrate stabilization, followed by
replacement with neutral PEG.17 Without introduction of the cationic ligands to the HAuNS,
histological analysis of PEG-HAuNS-treated mice showed no significantly structural change
of the liver cells. However, an elevated serum LDH level as well as irreversible change in
the proteomic profile of the liver at 3 months post-injection in this study, suggested need for
further investigation of the potential long-term toxicity of PEG-HAuNS. This result was
consistent with the previous finding that the i.v. injected gold nanoparticles caused changes
of gene expression in the liver and spleen ascribed to the non-metabolizable properties of
gold.13
CONCLUSIONS
In summary, this study specified biodegradability of PEG-HCuSNPs that was distinct from
non-metabolizability of PEG-HAuNS. The comparative results between the two types of
nanoparticles revealed that the nanotoxicity was tightly related to the degradability of the
nanoparticles. The current findings advance further studies on design of biodegradable and
safe PEG-HCuSNPs for photothermal therapy in clinics. Moreover, we for the first time
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explored the MALDI-TOF IMS to evaluate nanotoxicity, which determined changes in the
molecular composition of liver tissues administered with nanoparticles. The information
obtained from proteomic profiling by MALDI-TOF IMS complements results from
conventional toxicity test, providing a comprehensive understanding of nanotoxicity.
EXPERIMENTAL SECTION
Materials
The chemicals used were purchased from Sigma-Aldrich Chemical, Inc. unless mentioned
specifically. BALB/c mice (both 6–8 weeks, male and female) were ordered from Charles
River Laboratories International, Inc. All animal experiments were conducted in compliance
with the guidelines for the care and use of research animals established by the University of
Rhode Island Institutional Animal Care and Use Committee (IACUC).
Nanoparticles synthesis and characterization
HCuSNPs were synthesized according to our previously reported method.18 The HCuSNPs
were centrifuged at 15,557 g for 15 min at room temperature, and washed twice with
distilled water. After resuspended in 4.8 mL of water, the nanoparticles were mixed with
200 μL of PEG-SH (5 mg/mL, MW 5,000) for 12 h at room temperature to obtain PEG-
HCuSNPs. The nanoparticles were then centrifuged, and washed twice with distilled water.
The HAuNS were synthesized and pegylated according to the previous report.17 The
nanoparticles were deposited on the grid and directly examined under the TEM (JEOL
JEM2100). The absorbance spectrum was measured by DU800 UV/Vis spectrophotometer
(Beckman Coulter). The nanoparticles were dissolved in aqua regia for the inductively
coupled plasma mass spectrometer (ICP-MS) (Model: X7, Thermo Electron Corporation)
quantitative analysis of Cu or Au.51
Biodistribution of nanoparticles in BALB/c mice
BALB/c mice were divided into ten experimental groups (5 mice per group). PEG-
HCuSNPs (20 mg/kg of Cu) or PEG-HAuNS (20 mg/kg of Au) were injected through tail
vein. Mice were sacrificed at 1 day, 1 week, 2 weeks, 1 month and 3 months post injection.
Blood was withdrawn, and tissues including heart, liver, spleen, lung and kidney were
collected for ICP-MS analysis. Half of liver tissue in each group was cryosectioned for
histological analysis.
For ICP-MS analysis, the tissue samples were digested using a Mars 5 microwave system
(CEM Corporation). In brief, approximately 20 mg of tissue samples were weighed and
transferred into digestion vessels. After adding 1 mL of nitric acid to each vessel, the
samples were digested for 10 min with the power of 600 W. Afterwards, 0.2 mL of digested
solution was added to 9.8 mL of deionized water for ICP-MS analysis. The calibration
standards of Cu and Au in four concentrations (0, 50, 100, and 200 ng/mL) were analyzed
with each batch of samples. The average recovery efficiencies of Cu and Au were 98 – 102
%.
For histological analysis of CuS nanoparticles in liver, the tissues were fixed with 4%
paraformaldehyde at room temperature for 20 min. A 5.0% silver nitrate aqueous solution
was prepared as solution A. An aqueous solution containing 2% hydroquinone and 5% citric
acid was prepared as solution B. After rinsed with deionized water, the slices were
developed in freshly filtered solution of 1 part A and 5 parts B for 3 min. Following
deionized water washing, the slices were counterstained with hematoxylin. In separate
slices, following sliver staining, antigen was retrieved by proteinase K for 10 min at room
temperature. The slices were stained with rat anti-mouse CD68 monoclonal antibody (1:100,
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AbD SeroTec) at 4°C overnight, followed by peroxidase-goat anti-rat IgG (1:200, Life
Technologies) for 1 h at room temperature. The samples were developed using
diaminobenzidine tetrahydrochloride (DAB) kit (Life Technologies) according to the
manufacturer’s suggested protocol followed by hematoxylin counterstaining.
For histological analysis of distribution of HAuNS in liver, the proteinase K treated slices
were stained with rat anti-mouse CD68 monoclonal antibody (1:100) followed by Alexa
Fluor 594-conjugated goat anti-rat IgG (Life Technologies) for 1 h at room temperature. The
cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). The slices were
examined under the Nikon fluorescence microscope equipped with a dark field condenser.
Urine and feces sample collection and analysis
BALB/c mice were randomly divided into 2 groups (n=3). The mice were i.v. injected with
PEG-HCuSNPs (20 mg/kg of Cu) or PEG-HAuNS (20 mg/kg of Au). The mice were then
transferred to mouse metabolic cages (Tecniplast) for urine and feces collection up to one
month. Another 3 mice without injection were used as control. The mice were allowed to
access food and water freely. The urine samples were centrifuged at 15,871 g for 15 min to
separate the pellet and supernatant. Both urine and feces samples were digested as the above
described method for analysis of Cu or Au content.
For TEM imaging, urine samples collected 24 h following nanoparticles injection, were
directly deposited on the grid without counterstaining. For TEM analysis of blood sample,
the blood was withdrawn 3 h after i.v. injection of PEG-HCuSNPs (20 mg/kg of Cu). The
blood was transferred to Eppendorf tube with heparin. Plasma was collected after
centrifugation at 845 g for 5 min. The pellet containing nanoparticles was separated from the
plasma by further centrifugation at 15,871 g for 15 min. Resuspended in water, the plasma
pellet was deposited on the grid without counterstaining.
In vitro cytotoxicity
Murine macrophage RAW264.7 cells (ATCC) were seeded in 96-well plate at a density of
10,000 cells per well and incubated for 24 h to allow the cells to attach. The cells were
exposed to PEG-HCuSNPs, or PEG-HAuNS, or CuCl2 with various Cu or Au
concentrations in DMEM plus 10% FBS. After 24 h, cell viability was measured using the
MTT assay according to the manufacturer suggested procedures. The data represented the
means of quadruplicate measurements.
In a separate study, primary hepatocytes were isolated from BALB/c mice by our modified
two-step collagenase digestion method.33 Washed with Williams’ Medium E for three times,
the hepatocytes were suspended in same medium containing 35% percoll. The resulting cell
pellet was then suspended in Williams’ Medium E containing 10% FBS, insulin transferrin-
sodium selenite (ITS) supplement, and dexamethasone (100 nM). Cell viability was
determined by trypan blue exclusion. Hepatocytes were plated onto collagen-coated 96-well
culture plates at a density of 10,000 cells per well. The cells were allowed to attach for 4 h at
37°C. Culture plates were then gently swirled, and the medium containing unattached cells
was aspirated. Same fresh medium was added.34 After 2 d, the cells were exposed to PEG-
HCuSNPs, or PEG-HAuNS, or CuCl2 with different Cu or Au concentrations in the same
medium. After 24 h, cell viability was measured using the MTT assay.
Blood biochemistry and histology
Male BALB/c mice were randomly divided into 7 groups (n = 5). The mice received an i.v.
injection of PEG-HCuSNPs (20 mg/kg of Cu) or PEG-HAuNS (20 mg/kg of Au). Blood
samples were collected at 7 day, 1 month or 3 months after nanoparticle injection for
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chemical analysis. Mice without treatment were used as control. For histological evaluation,
portions of the liver collected were fixed in 10% buffered formalin-saline at 4 °C overnight
and then embedded in paraffin blocks. Tissue sections (5-μm thickness) were stained with
hematoxylin and eosin (H&E).
MALDI-TOF IMS analysis
Tissue sections of 5 μm were applied onto ITO (Indium Teen Oxide) one-side coated,
conductive glass slides. A matrix solution (synapic acid, 10 mg/mL in ACN/TFA 0.2%, 6:4,
v/v) was then applied using Image Prep (Bruker Daltonics). Spectra were collected across
the entire tissue area using the Ultraflex III MALDI-TOF/TOF instrument (Bruker
Daltonics) with a SmartBeam laser operating at 100 Hz in linear mode over a mass range of
m/z 2,000 to 20,000. A laser spot diameter of 100 nmu;m and a raster width of 100 μm were
used. Using the FlexImaging software (Bruker Daltonics), teaching points were generated to
ensure the correct positioning of the laser for spectral acquisition. The software exports the
specific geometry of the tissue to be analyzed, and an instrument-specific automated method
is created, which generates a grid across the tissue of spots where the laser will acquire data.
Calibration was done externally using a protein standard mixture in the mass range of m/z
6,000 to 16,500. The intensity of each signal over the entire mass range acquired is plotted
as a function of location on the tissue, allowing the visualization of the location of each m/z
detected. These images were generated and visualized using FlexImaging software.
Consequently, the spectra derived from regions of interest in each tissue were exported
using the FlexImaging software for profile analysis. Normalizing, baseline subtracting, peak
defining and comparison of multiple spectra were performed automatically using
ClinProtTools software. PCA and 2-D peak distribution were managed by an external
MATLAB software tool, which was integrated in ClinProTools.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
TEM of (A) HCuSNPs and (B) HAuNS. Bars, 50 nm. (C), Experimental absorbance spectra
of the nanoparticles (27 μg/mL of Cu or Au) in water or mouse serum.
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Figure 2.
(A), Biodistribution of Cu or Au in BALB/c mice following i.v. injection of PEG-HCuSNPs
(20 mg/kg of Cu) or PEG-HAuNS (20 mg/kg of Au). Data are expressed as percentage of
injected dose per gram of tissue (%ID/g tissue) and are presented as mean ± standard
deviation (n=5). *, P < 0.05; **, P < 0.01 for %ID/g of Cu v.s. %ID/g of Au. (B), Relative
liver and spleen accumulation of Cu or Au postinjection. Data are expressed as percentage
of Cu or Au accumulation compared to 1-day postinjection groups and are presented as
mean ± standard deviation (n=5). *, P < 0.05; **, P < 0.01 for relative accumulation of Cu
v.s. that of Au.
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Figure 3.
Renal excretion of PEG-HCuSNPs. (A), TEM of small CuS nanoparticles (SCuSNPs,
arrows) in urine collected from BALB/c mice at 24 h following i.v. injection of PEG-
HCuSNPs. (B), TEM of HCuSNPs in water. Arrow, small CuS crystalline structure. (C–E),
TEM of CuS nanoparticles separated from plasma at 3 h following i.v. injection of PEG-
HCuSNPs. Most CuS nanoparticles were intact PEG-HCuSNPs (C), while there were a few
SCuSNPs (D and E, arrows). Bars, A–E, 50 nm; inlet bars, 5 nm.
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Figure 4.
Cumulative renal excretion of Cu (A) and Au (B) from mice injected with PEG-HCuSNPs
(20 mg/kg of Cu) or PEG-HAuNS (20 mg/kg of Au). The “t” of X-axis represents the
median time between the starting and ending time points of each urine sample collection.
Each urine sample was separated into pellet and supernatant by high speed centrifugation
(15,871 g, 15 min). The total amount of Cu or Au of each urine sample was the sum of the
amount in pellet and that in supernatant. %ID represents percentage of injected dose. Data
are presented as mean ± standard deviation (n=3).
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Figure 5.
Histological analysis of nanoparticles distribution in liver. (A), Distribution of CuS
nanoparticles in liver. Black, CuS nanoparticles with sliver staining. Blue, cell nuclei
counterstained with hematoxylin. Brown colored cells in lower image of each panel, Kupffer
cells immunostained with rat anti-mouse CD68 antibody followed by peroxidase-goat anti-
rat IgG and diaminobenzidine tetrahydrochloride (DAB) development. Bars, 50 μm. (B),
Distribution of HAuNS in liver. Pseudo-green, scattering signal of HAuNS under dark field.
Blue, DAPI-stained cell nuclei. Red, Kupffer cells immunostained with rat anti-mouse
CD68 antibody followed by Alexa Fluor 549-conjugated goat anti-rat IgG. Bars, 50 μm.
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Figure 6.
The cumulative excreted Cu (A) and Au (B) in the feces from mice injected with PEG-
HCuSNPs (20 mg/kg of Cu) or PEG-HAuNS (20 mg/kg of Au). The cumulative Cu or Au in
the feces was collected at 1–9 d, 10–20 d and 21–30 d following administration,
respectively. The amount of Cu or Au in “1–30 d” was the sum of these three consecutive
time periods. %ID represents percentage of injected dose. Data are presented as mean ±
standard deviation (n=3).
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Figure 7.
(A), Viability of RAW264.7 cells and primarily cultured mouse hepatocytes exposed to
different concentration of Cu or Au. For CuCl2 and PEG-HCuSNPs treatment groups, X-
axis represents the Cu concentration; for PEG-HAuNS treatment group, X-axis represents
the Au concentration. Cell viability was measured by the MTT assay. Data are plotted as the
percentage of viable cells compared to untreated controls. Each value represents mean ±
standard deviation (n=4). (B), The mouse serum level of biochemical variables 7 d, 1 m, or 3
m after i.v. injection of PEG-HCuSNPs (20 mg/kg of Cu, filled boxes) or PEG-HAuNS (20
mg/kg of Au, open boxes). “Ctrl” represents mice without any treatment. Values are the
means ± standard deviation, n = 5. Significant difference in the parameters between
nanoparticle-treated groups and the control (*, p < 0.05; **, p < 0.01). ALT, alanine
aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; ALP,
alkaline phosphatase; BUN, blood urea nitrogen. (C), H&E staining of mouse liver samples
7 d or 3 m following i.v. injection of PEG-HCuSNPs (20 mg/kg of Cu), or PEG-HAuNS (20
mg/kg of Au). Bars, 50 μm.
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Figure 8.
MALDI-TOF IMS analysis of frozen liver slices from mice with or without i.v. injection of
PEG-HCuSNPs (20 mg/kg of Cu). (A–B), 2-D peak distribution views (A) using p-value t-
test ANOVA, significant peaks (pk186, 8566 Da; pk94, 4964 Da) and (B) using difference
average, significant peaks (pk94, 4964 Da; pk51, 3458 Da). The liver tissues were collected
at 1 d (pink), 7 d (red), or 3 m (green) after the injection. Blue, liver from mice without any
treatment (Control). The axes show the peak area/intensity values with respect to the
significant peaks. The ellipse represents 95% confidence interval. Arrows represent
direction of disparity of the distributions over time. (C), Imaging of mass peaks in liver with
significant difference between the nanoparticle-treated and untreated samples. Each
represents the distribution of one peak with m/z noted in the tissue slice. (D), Scores (top
row) and loading (bottom row) outputs of principal component analysis (PCA). During the
calculation of the principal components (PCs), the variables (peaks) obtained different
loadings in dependence on their contribution to the explained variance of a PC. Pink, 1 d;
Red, 7 d; Green, 3 m; Control, blue.
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Figure 9.
MALDI-TOF IMS analysis of frozen liver slices from mice with or without i.v. injection of
PEG-HAuNS (20 mg/kg of Au). (A–B), 2-D peak distribution views (A) using p-value t-test
ANOVA, significant peaks (pk41, 4737 Da; pk47, 4964 Da) and (B) using difference
average, significant peaks (pk47, 4964 Da; pk113, 14970 Da). The liver tissues were
collected at 1 d (pink), 7 d (red), or 3 m (green) after the injection. Blue, liver from mice
without any treatment (Control). The axes show the peak area/intensity values with respect
to the significant peaks. The ellipse represents 95% confidence interval. Arrows represent
direction of disparity of the distributions over time. (C), Imaging of mass peaks in liver with
significant difference between the nanoparticle-treated and untreated samples. Each
represents the distribution of one peak with m/z noted in the tissue slice. (D), Scores (top
row) and loading (bottom row) outputs of principal component analysis (PCA). During the
calculation of the principal components (PCs), the variables (peaks) obtained different
loadings in dependence on their contribution to the explained variance of a PC. Pink, 1 d;
Red, 7 d; Green, 3 m; Control, blue.
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Scheme 1.
Illustration of disposition of HCuSNPs in body following i.v. injection.
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